Edison Investment Research - Pharmaceuticals & healthcare - Destiny Pharma: Destiny Pharma’s imminent Phase IIb study start dominated the FY18 results announcement. The US Phase IIb study of XF-73 is open and recruiting with results expected around YE19. Destiny’s operating loss increased to £6.1m (vs £3.2m in FY17) with R&D costs of £3.5m (vs £0.4m in FY17) comprising the majority of operational expense. Cash at the end of FY18 was £12.1m, which gives Destiny a runway well into 2020.
ISIN: GB00BDHSP575
Original Article: Destiny Pharma (DEST) - Well-funded with clinical results in a year